Pharmaco-imaging and molecular radiotherapy services

Pharmaco-Imaging

Discovery Services

Medicinal Chemistry In vitro biology DMPK Bioanalysis Pharmaco-Imaging Radiochemistry In vivo Pharmacology

Pharmaco-imaging, a non-invasive approach to support proof of concept in pharmacology

Imaging is a non-invasive tool for pharmacology enabling to significantly reduce the number of animals and to efficiently monitor:

  • the biodistribution of drugs
  • the expression and engagement of in vivo targets
  • the effect of therapeutic treatments
  • their mechanism of action
  • their pharmacodynamic
  • the development of their MRT counterparts (Drive-MRT)
Pharmaco-Imaging Studies in Drug Discovery | Oncodesign
Preclinical Imaging Services | Multimodal technologies to understand the pharmacology

Oncodesign Services has added pharmaco-imaging to its pharmacology platform in 2004, integrating along the years imaging multimodalities:

  • MRI 4.7T
  • Nuclear imaging (PET/CT, SPECT/CT, PET/MR)
  • Optical imaging (Bioluminescence, Fluorescence)
  • Ultrasound

 

Oncodesign Services’ in vivo multi-modal imaging platform can be used for biodistribution studies, tumor tracking and to detect biomarkers of activity. Pharmaco-imaging studies often utilize radioisotopes, leveraging the capabilities of our bioconjugation and radiochemistry expertise. It is applicable to small molecules, biologics, nanoparticles.

Oncodesign Services support radiopharmaceuticals development for Theranostics.

GET IN TOUCH

DRIVE-MRT: a premium “nuclear medicine” solution in Oncology​

DRIVE-MRT is part of our continuous improvement in the integrated drug discovery support. Oncodesign Services and its strategic partners Covalab, CheMatech, and ABX-CRO are applying their expertise in the rationalization, design, and optimization of targeted radiopharmaceutical agents.

More information

Pharmimage® – a non-invasive pharmaco-imaging capability

Our technology module, Pharmimage® is designed to monitor the effect of treatments and to define effective translational biomarkers in precision medicine. It helps to answer questions using non–invasive, whole–body techniques:

  • Is the target expressed? (Diagnosis of the disease, heterogeneity of target expression, distribution of the target in metastatic cancer, CNS, cardiology, etc.)
  • Does the drug reach the target? (Pharmacokinetics, biodistribution, blood–brain barrier crossing, etc.)
  • Is the target inhibited/activated, and does this induce biochemical and biological changes? (Pharmacodynamics, immunomonitoring, optimal biological dose, etc.)
  • Are there any potential toxicities and drug interactions? (Safety, study on drug combinations, metabolism, etc.)
  • Are these changes related to a clinical criterion? (Efficacy of a new treatment, monitoring of the immune response to a vaccine, emergence of resistance in precision medicine, etc.)
  • Can subpopulations of responders be determined? (Translational biomarker)